Zinpro Corporation Announces Executive Leadership Changes
Anderson Promotes Scrimgeour to President & CEO, and Sheffer Joins Company as COO
EDEN PRAIRIE, Minn., June 13, 2017 (GLOBE NEWSWIRE) -- Zinpro Corporation announces that its owner, Michael D. Anderson, has promoted William Scrimgeour to be the company's next president and CEO. The transfer in CEO responsibilities to Scrimgeour will allow Anderson to concentrate more time and energy on his role as chairman of the board of directors. Anderson has held his positions as CEO and board of directors chairman for Zinpro Corporation since May, 1992.
The change in responsibilities will enable Anderson to more effectively lead the board of directors to set the company's future course and to provide strategic direction as the company continues to expand globally. "In the next five years, we anticipate our company's growth to increase rapidly worldwide, and we need to not only enhance our efforts in areas that will count most, but also add to our leadership team as we prepare for the future," says Anderson. "Handing off my CEO responsibilities will also allow me to concentrate more on how to expand the scope of our company's positive global impact, both on animals and people."
Anderson's successful tenure as CEO is marked by many accomplishments since taking on the role from his father and founder, Dean Anderson. Over the past 25 years, Michael Anderson has led the company to develop and launch more than 75 new products, to expand sales into 60 additional countries, to build three manufacturing facilities and to establish nine international subsidiaries and two new business ventures. In addition, he has guided the expansion of Zinpro Corporation into a leading global exporter of Performance Minerals®.
Scrimgeour takes on his new position as president and CEO, having previously served Zinpro Corporation as president and Chief Operating Officer (COO) since 2008. "Over the last nine years, Bill has excelled in overseeing all company departments and managing day-to-day operations," says Anderson. "I'm confident Bill will be instrumental in helping Zinpro to continue to meet the demand from an ever-increasing global customer base who desires our products and services to improve animal wellness and performance."
With Scrimgeour taking on the position of CEO, the company also announces that Rob Sheffer has joined Zinpro Corporation as its new COO. Sheffer comes to Zinpro with more than 25 years of leadership experience - most of it with a global animal nutrition company. Sheffer's wide-ranging leadership experience includes positions as president and CEO, group director, managing director, regional sales leader and branch manager. He also served as board chair for the American Feed Industry Association from 2015-2016.
"Rob has a proven track record for developing, motivating and inspiring teams to achieve business growth, including growth in global markets," says Scrimgeour. "I'm very pleased to welcome him to Zinpro to be our next COO. His extensive leadership experience in the feed and animal nutrition industries will serve him well, and Zinpro well, as our company continues to expand worldwide."
As the industry leader in trace mineral nutrition for livestock and poultry, Zinpro is committed to delivering the technical expertise, products and educational tools needed to help customers improve the performance and profitability of their operations.
About Zinpro Corporation
More than 45 years ago, Zinpro Corporation pioneered the research and development of Performance Minerals®. As a family-owned, privately-held company, Zinpro Corporation's steady growth has come as a result of quality products, quality people and a focus on one thing: performance trace minerals for exceptional animal nutrition. Today, the company has regional sales offices located in nine countries and markets its products in more than 70 countries worldwide. For more information, visit zinpro.com, or call +1 952-983-4000.
Performance Minerals® is a registered trademark of Zinpro Corporation. ©2017 Zinpro Corp. All rights reserved.
For more information, contact:
Corporate Communications Specialist
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zinpro Corporation via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00 | Pressmeddelande
Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31 | Pressmeddelande
NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999. "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man
CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00 | Pressmeddelande
CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i
HemChecks avläsare kalibrerad med toppresultat - Regulatorisk20.11.2017 16:18 | Pressmeddelande
HemChecks avläsare kalibrerad med toppresultat Det medicintekniska bolaget HemCheck, som utvecklar ett patientnära test för detektion av hemolys, kan idag meddela att den digitala avläsare som utgör en del av bolagets produktkoncept Helge, kalibrerats med mycket gott resultat. Detta skedde genom studier i egen regi. Avläsaren kan nu färdigställas och produktkonceptet kommer därmed ett steg närmare CE-märkning. Som ett led i att färdigställa bolagets produktkoncept Helge har HemCheck under hösten utfört studier i egen regi med hjälp av blod från frivilliga bloddonatorer. Syftet var att kalibrera avläsaren och på så sätt möjliggöra en patientnära avläsning av hemolys, det vill säga redan på ett tidigt stadium avgöra om blodprovet är användbart och kan ska skickas till analys. -Enkelt utryckt har vi lärt avläsaren att mäta hemolys på våra engångstester. Det är en viktig milstolpe och en stor framgång. Nu känner vi oss redo
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum